Stocks › ASND

Ascendis Pharma A/S

ASND·Nasdaq·USD
$252.73
-3.23 (-1.26%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
ASND
Ascendis Pharma A/S · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
ASNDS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair

Congressional Trades

Recent trades of ASND by members of U.S. Congress · 3 on record
All congressional trades →
PoliticianStockTypeFiledTraded
Gary J. PalmerGary J. PalmerHouse · R · AL ASNDAscendis Pharma A/S · Stock Sale
$1,001 - $15,000
Nov 7, 2018 Oct 5, 2018 Filing ↗
Gary J. PalmerGary J. PalmerHouse · R · AL ASNDAscendis Pharma A/S · Stock Purchase
$1,001 - $15,000
Sep 29, 2018 Aug 6, 2018 Filing ↗
Gary J. PalmerGary J. PalmerHouse · R · AL ASNDAscendis Pharma A/S · Stock Purchase
$1,001 - $15,000
Sep 29, 2018 Jul 12, 2018 Filing ↗

Whale Activity

Position changes in ASND reported for 2026-09-30 by 382 institutional filers
Increased: 138New: 74Held: 24Decreased: 89Closed: 40No prior filing: 17
  • Increased138
  • New74
  • Held24
  • Decreased89
  • Closed40
  • No prior filing17
FilerSharesValueChange
RA CAPITAL MANAGEMENT, L.P.10.3M$2.34Bheld
T. Rowe Price Investment Management, Inc.8.2M$1.87Bincreased
WESTFIELD CAPITAL MANAGEMENT CO LP5.1M$1.17Bincreased
Avoro Capital Advisors LLC5.0M$1.15Bdecreased
Janus Henderson Group Ltd.3.6M$828.5M—
FMR LLC3.4M$785.0Mdecreased
WELLINGTON MANAGEMENT GROUP LLP3.1M$699.5Mincreased
BlackRock, Inc.2.3M$520.4Mincreased
Artisan Partners Limited Partnership2.1M$474.6Mdecreased
MASSACHUSETTS FINANCIAL SERVICES CO /MA/1.9M$431.9Mincreased
Capital International Investors1.4M$322.9Mdecreased
FRANKLIN TEMPLETON INC1.1M$285.9Mdecreased

Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.

Insider Trading

Net shares bought (+) or sold (−) on the open market by ASND insiders, by quarter · Form 4
-20.0K-10.0K010.0K20.0K2025 Q1: 02025 Q12025 Q2: 02025 Q22025 Q3: 02025 Q32025 Q4: 02025 Q42026 Q1: 02026 Q12026 Q2: -18.2K2026 Q22026 Q3: -1,2362026 Q32026 Q4: -20.0K2026 Q4

Recent Insider Transactions

14 transactions on record · newest first
All insider activity →
InsiderTypeSharesPriceValueDate
PEDERSEN ANNI LOTTE KIRSTINE SONDERBJERGEVP & Chief Admin Officer Sale −20.0K $263.89 $5.3M Nov 17, 2026 Form 4 ↗
Bodenhoff MadsSVP & PAO Sale −3,000 $270.19 $811K Sep 8, 2026 Form 4 ↗
Bodenhoff MadsSVP & PAO Option exercise +3,000 $110.00 $330K Sep 8, 2026 Form 4 ↗
HOLTUG LARSDirector Sale −236 $264.13 $62K Sep 2, 2026 Form 4 ↗
BIENAIME JEAN JACQUESDirector Purchase +900 $246.91 $222K Aug 14, 2026 Form 4 ↗
BIENAIME JEAN JACQUESDirector Purchase +1,100 $245.85 $270K Aug 14, 2026 Form 4 ↗
SMITH SCOTT THOMASEVP & Chief Financial Officer Purchase +100 $219.00 $22K Jun 2, 2026 Form 4 ↗
BIENAIME JEAN JACQUESDirector Purchase +100 $223.50 $22K May 29, 2026 Form 4 ↗
BIENAIME JEAN JACQUESDirector Purchase +200 $222.30 $44K May 29, 2026 Form 4 ↗
BIENAIME JEAN JACQUESDirector Purchase +200 $223.76 $45K May 29, 2026 Form 4 ↗
SMITH SCOTT THOMASEVP & Chief Financial Officer Purchase +250 $223.32 $56K May 29, 2026 Form 4 ↗
BIENAIME JEAN JACQUESDirector Purchase +200 $239.37 $48K May 26, 2026 Form 4 ↗
BIENAIME JEAN JACQUESDirector Purchase +200 $236.24 $47K May 26, 2026 Form 4 ↗
JENSEN FLEMMING STEENSee Remarks Sale −19.5K $238.49 $4.6M May 11, 2026 Form 4 ↗

Fund Holders

Mutual funds and ETFs holding ASND · SEC Form N-PORT
FundSharesValue% of fundAs of
Ultra Fund
American Century Mutual Funds, Inc.
664.0K$162.0M0.63%Jul 31, 2026
Bridge Builder Small/Mid Cap Growth Fund
Bridge Builder Trust
473.3K$126.2M1.13%Jun 30, 2026
T. Rowe Price Capital Appreciation Equity ETF
T. Rowe Price Exchange-Traded Funds, Inc.
350.1K$93.4M1.26%Jun 30, 2026
Touchstone Strategic Trust-Touchstone Mid Cap Growth Fund
Touchstone Strategic Trust
313.9K$83.7M3.68%Jun 30, 2026
LargeCap Growth Fund I
Principal Funds, Inc
310.4K$75.7M1.33%Jul 31, 2026
Focused Dynamic Growth Fund
American Century Growth Funds, Inc.
213.8K$52.2M2.61%Jul 31, 2026
iShares Russell 1000 Growth ETF
iShares Trust
179.6K$47.9M0.04%Jun 30, 2026
International Equity Fund
Principal Funds, Inc
174.9K$42.7M0.66%Jul 31, 2026
Bridge Builder Tax Managed Small/Mid Cap Fund
Bridge Builder Trust
112.0K$29.9M0.84%Jun 30, 2026
VANGUARD RUSSELL 1000 GROWTH INDEX FUND
VANGUARD SCOTTSDALE FUNDS
76.5K$20.1M0.04%Aug 31, 2026

Mutual funds and ETFs whose N-PORT filings list ASND's shares (CUSIP K08588103), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.

Activist & Passive Stakes

Schedule 13D / 13G beneficial-ownership filings
  • T. Rowe Price Investment Management, Inc.SCHEDULE 13G/A · passive (13G) · 8.2M shares12.4%
    Nov 16, 2026 · ↗
  • Abigail P. JohnsonSCHEDULE 13G/A · passive (13G) · 3.4M shares5.2%
    Nov 5, 2026 · ↗
  • FMR LLCSCHEDULE 13G/A · passive (13G) · 3.4M shares5.2%
    Nov 5, 2026 · ↗
  • Artisan Partners Limited PartnershipSCHEDULE 13G/A · passive (13G) · 2.6M shares4.2%
    Aug 13, 2026 · ↗
  • Artisan Investments GP LLCSCHEDULE 13G/A · passive (13G) · 2.6M shares4.2%
    Aug 13, 2026 · ↗
  • Artisan Partners Holdings LPSCHEDULE 13G/A · passive (13G) · 2.6M shares4.2%
    Aug 13, 2026 · ↗
  • Artisan Partners Asset Management Inc.SCHEDULE 13G/A · passive (13G) · 2.6M shares4.2%
    Aug 13, 2026 · ↗
  • JANUS HENDERSON GROUP PLCSCHEDULE 13G/A · passive (13G) · 3.7M shares6.0%
    May 15, 2026 · ↗
  • Capital International InvestorsSCHEDULE 13G/A · passive (13G) · 2.0M shares3.2%
    May 14, 2026 · ↗
  • T. Rowe Price Investment Management, Inc.SCHEDULE 13G/A · passive (13G) · 6.5M shares10.5%
    May 7, 2026 · ↗

Corporate Lobbying

Estimated quarterly lobbying spending reported under the LDA, filings naming Ascendis Pharma A/S as client

No lobbying filings found naming Ascendis Pharma A/S as the client.

Government Contracts

Federal awards to Ascendis Pharma A/S · USAspending

No federal contract awards found for Ascendis Pharma A/S.

U.S. Patents

Recent USPTO applications naming Ascendis Pharma A/S

No USPTO patent applications found for Ascendis Pharma A/S.

Annual Financials

From ASND's 10-K filings · XBRL

SEC's XBRL figures for Ascendis Pharma A/S include no full-year results from a 10-K in US dollars, so there is no table to show. Companies based abroad usually report annually on Form 20-F instead.

Stock Splits

Every split and reverse split in the price history

No stock splits in ASND's price history.

Material Events (8-K)

Corporate events filed with the SEC

No 8-K filings on record.

About Ascendis Pharma A/S

From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersHELLERUP
IncorporatedG7